American Battery Technology Shares Rise 20% After $20 Million Award From DoE
By Chris Wack
American Battery Technology shares were rose after the company said it was selected for a $20 million award through the Qualifying Advanced Energy Project Credits program granted by the U.S. Department of Treasury's Internal Revenue Service.
Shares were up 20% to $1.96 in recent trading. The stock hit its 52-week low of $1.56 on April 2, and is down 85% in the past 12 months.
The award follow a technical and economic review process performed by the U.S. Department of Energy, which evaluated the feasibility of applicant facilities to advance the buildout of critical material recycling, processing and refining infrastructure.
American Battery said the $20 million award can be used both for the reimbursement of capital expenditures spent to date, and also for equipment and infrastructure for additional value-add operations at its battery recycling facility in the Tahoe-Reno Industrial Center in Storey County, Nevada.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
April 03, 2024 10:41 ET (14:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track